Diabetes Complications Tied to Higher Risk for Gum Disease
By Lori Solomon HealthDay Reporter
THURSDAY, Sept. 19, 2024 -- Neuropathy and retinopathy are positively associated with moderate/severe periodontitis, according to a study published online Aug. 5 in the Journal of Dental Research.
Fernando Valentim Bitencourt, D.D.S., from Aarhus University in Denmark, and colleagues investigated the association between individual and combined diabetic microvascular complications (i.e., neuropathy and retinopathy) and moderate/severe periodontitis. The analysis included 15,922 individuals with type 2 diabetes participating in the Health in Central Denmark study.
The researchers found that in an adjusted analysis, diabetic neuropathy (odds ratio [OR], 1.36) and retinopathy (OR, 1.21) were associated with moderate/severe periodontitis. The coexistence of microvascular complications increased the odds of moderate/severe periodontitis (OR, 1.51). There was an additive effect for modification of dyslipidemia, indicating a positive relative excess risk due to interaction of 0.24 for neuropathy, 0.11 for retinopathy, and 0.44 for both complications. Unmeasured confounders and microvascular complication definitions were ruled out as explanatory factors in a sensitivity analysis. There was an association between diabetic neuropathy and retinopathy, individually and combined, with moderate/severe periodontitis. Dyslipidemia had an additive positive effect modification on diabetic microvascular complications, increasing the odds of moderate/severe periodontitis.
"Dentists should consider recommending a screening for microvascular complications in persons with type 2 diabetes who have moderate/severe periodontitis, especially those with dyslipidemia," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
ADA: Ecnoglutide Yields Superior, Sustained Reduction in Body Weight
MONDAY, June 23, 2025 -- For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon like peptide 1 receptor agonist...
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
FRIDAY, June 20, 2025 -- For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and...
DASH Diet for Diabetes With Low Sodium Reduces BP in Those With Diabetes
WEDNESDAY, June 18, 2025 -- The Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) diet with lower sodium is tied to clinically meaningful blood pressure reduction in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.